Evidence map›Paper›PMID 38587424›Full record

ArticlemBio2024

Amaris J Cardenas, Keena S Thomas, Mary W Broden, Noel J Ferraro, Marcos M Pires, Constance M John, Gary A Jarvis, Alison K Criss

Open access · goldAbstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Neutrophil CEACAMs and the Inflammatory Response toJournal of innate immunity · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

  • Update of
    2024
5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Amaris J CardenasDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.
Keena S ThomasDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.
Mary W BrodenDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.
Noel J FerraroDepartment of Chemistry, University of Virginia, Charlottesville, Virginia, USA.
Marcos M PiresDepartment of Chemistry, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0002-5676-0725
Constance M JohnVA Medical Center and University of California, San Francisco, San Francisco, California, USA.
Gary A JarvisVA Medical Center and University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-7576-3702
Alison K CrissDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0001-7738-3757
University of Virginia · USSan Francisco VA Medical Center · US

Funding

INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
The Gonorrhea Vaccine Cooperative Research CenterU19AI144180 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI CRISS, ALISON K · 2019 to 2023
$10.7M
Survival of Neisseria gonorrhoeae after primary human neutrophil challengeR01AI097312 · NIAID · UNIVERSITY OF VIRGINIA · PI CRISS, ALISON K · 2012 to 2022
$4.6M
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.U01AI162457 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUNCAN, JOSEPH A · 2021 to 2025
$3.9M
Unraveling Bacterial Cell Wall Biosynthesis and Sensing via Synthetic AnalogsR35GM124893 · NIGMS · UNIVERSITY OF VIRGINIA · PI Marcos M. Pires · 2017 to 2026
$3.6M
Survival of Neisseria gonorrhoeae after primary human neutrophil challengeR37AI097312 · NIAID · UNIVERSITY OF VIRGINIA · PI Alison K Criss · 2025 to 2026
$1.1M
Investigating the role of lipooligosaccharide sialylation in Neisseria gonorrhoeae-neutrophil interactionsF31AI157528 · NIAID · UNIVERSITY OF VIRGINIA · PI CARDENAS, AMARIS J. · 2021 to 2023
$71k
Targeting of LOS for Treatment of Antibiotic-Resistant Neisseria gonorrhoeaeI01BX000727 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI JARVIS, GARY A · 2011 to 2025
–
BLRD VA I01 BX000727BLRD VA IK6 BX005798NIAID NIH HHS F31 AI157528NIAID NIH HHS R01 AI097312NIAID NIH HHS R37 AI097312NIAID NIH HHS T32 AI007046NIAID NIH HHS U01 AI162457NIAID NIH HHS U19 AI144180NIGMS NIH HHS R35 GM124893
6 · The paper itself

Abstract

Gonorrhea, caused by the bacterium IMPORTANCE:

Indexed as

GonorrheaN-Acetylneuraminic AcidNeisseria gonorrhoeaeNeutrophil ActivationNeutrophilsSialic Acid Binding Immunoglobulin-like LectinsBacterial Outer Membrane ProteinsComplement System ProteinsHost-Pathogen InteractionsHumansImmune EvasionLipopolysaccharidesRespiratory BurstBacterial Outer Membrane ProteinsComplement System Proteinslipid-linked oligosaccharidesLipopolysaccharidesN-Acetylneuraminic AcidOpa protein, NeisseriaSialic Acid Binding Immunoglobulin-like LectinsdegranulationgonorrheainfectionlipooligosaccharideNeisseria gonorrhoeaeneutrophilsreactive oxygen speciessialylation

Identifiers

PMID38587424
PMCPMC11078009
OpenAlexW4394568825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.